Mitochondria-associated membranes (MAMs) and inflammation.
Missiroli S, Patergnani S, Caroccia N, Pedriali G, Perrone M, Previati M, Wieckowski MR, Giorgi C. · 2018
Read Mitochondria-associated membranes (MAMs) and inflammation. by Missiroli S, Patergnani S, Caroccia N, Pedriali G, Perrone M, Previati M, Wieckowski MR, Giorgi C. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5832426.txt.
Introduction
Missiroli and co-authors review the contact zones where mitochondria meet the endoplasmic reticulum, and their grip on inflammation. Their review appeared in Cell Death & Disease. These zones, called MAMs, let the two organelles swap molecules fast. Immune alarms also gather there.
The NLRP3 inflammasome, a trigger of inflammatory cytokines, assembles at MAMs. The adaptor MAVS draws it to mitochondria during virus attack. Bacteria may strike the same platform to dodge immunity. Proteins living at MAMs also feature in Parkinson's and Alzheimer's diseases. The authors ask whether these small zones could serve as drug targets.
Catalog record
| CREATOR | Missiroli S, Patergnani S, Caroccia N, Pedriali G, Perrone M, Previati M, Wieckowski MR, Giorgi C. |
|---|---|
| YEAR | 2018 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 72 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mitochondria-associated membranes (MAMs) and inflammation By Sonia Missiroli, Simone Patergnani, Natascia Caroccia, Gaia Pedriali, Mariasole Perrone, Maurizio Previati, Mariusz R Wieckowski, Carlotta Giorgi Published in: Cell Death & Disease DOI: 10.1038/s41419-017-0027-2 ABSTRACT Abstract The endoplasmic reticulum (ER) and mitochondria are tightly associated with very dynamic platforms termed mitochondria-associated membranes (MAMs). MAMs provide an excellent scaffold for crosstalk between the ER and mitochondria and play a pivotal role in different signaling pathways that allow rapid exchange of biological molecules to maintain cellular health. However, dysfunctions in the ER–mitochondria architecture are associated with pathological conditions and human diseases. Inflammation has emerged as one of the various pathways that MAMs control. Inflammasome components and other inflammatory factors promote the release of pro-inflammatory cytokines that sustain pathological conditions. In this review, we summarize the critical role of MAMs in initiating inflammation in the cellular defense against pathogenic infections and the association of MAMs with inflammation-mediated diseases. FACTS - MAMs are a molecular platform essential for NLRP3 inflammasome formation. - The adaptor MAVS is required for NLRP3 mitochondrial localization and promotes its activation. - MAMs are directly involved in DAMP generation and in the cellular antiviral response. - Several MAM-resident proteins such as α-synuclein and presenilins play a crucial role in the pathogenesis of Parkinson’s disease and Alzheimer’s disease, respectively. OPEN QUESTIONS - How can such a small subcellular organelle have such an important function in NLRP3 inflammasome formation? - Could MAMs be considered a potential target for pathogenic bacteria to disrupt inflammasome activation and signaling during infection? - How could MAMs be developed to target or treat diseased conditions? - Is it feasible to assume that the integrity and functions of MAMs are relevant for therapeutic intervention? INTRODUCTION Studies over the past few decades have demonstrated that the endoplasmic reticulum (ER) and mitochondria are physically connected to form junctions termed mitochondria-associated membranes (MAMs). The MAMs fraction was first identified by J.E. Vance1 in 1990, who described the isolation of a unique membrane “fraction X” from rat liver enriched in a protein implicated in lipid synthesis and trafficking (for a detailed review, see ref. 2). Several biochemical techniques since have been described to isolate the MAM fraction, confirming that MAMs are composed of membrane fragments from both the ER and the outer mitochondrial membrane (OMM)3. In the past few years, different proteomics studies have identified the molecular components of the MAM fraction, demonstrating both from human fibroblast4 and from mouse brain5 that >1000 “MAM proteins” reside in this fraction. Recently, Sala-Vila et al. performed in-depth mass spectrometric analysis of the proteins composing MAM-enriched fractions and identified 1052 proteins including caveolin-1 (CAV1), which is an integral component of hepatic MAMs that determines the relative cholesterol content of these ER subdomains6. MAMs provide a platform that is fundamental for several cellular functions, such as calcium (Ca2+) homeostasis, autophagy, lipid metabolism, apoptosis, and tumor growth7,8, that allow rapid exchange of biological molecules to maintain cellular health. Therefore, the accurate connections and crosstalk between the ER and mitochondria are events that coordinate important functions of the two organelles and thus determine key aspects of cell fate. In fact, alterations in the composition of MAMs and the abnormal induction of this ER–mitochondria association lead to different pathological conditions9. For these reasons, several regulatory proteins, oncogenes, and tumor suppressors reside at MAMs in order to maintain normal cellular function and thereby preserve the intracellular equilibrium10,11. Considering that the ER–mitochondria interface is involved in several molecular pathways, it is not surprising that MAMs play an emerging role also in inflammatory signaling pathways. In fact, MAMs provide a critical site for inflammasome formation, are attractive targets for pathogenic bacteria and are relevant for the antiviral response (see the next paragraphs). Additionally, increasing evidence strongly implicates the involvement of MAMs in the initiation or progression of diseases associated with high inflammation, such as metabolic disorders and neurodegenerative diseases12. Finally, recent developments of promising therapeutics that target inflammasome activities at MAMs in inflammatory diseases have been reported. In this review, we discuss how MAMs represent a primary platform for initiating inflammatory mechanisms and how these networks might be manipulated to provide novel therapies for inflammatory diseases. MAMS AS A CRITICAL SITE FOR INFLAMMASOME FORMATION A link between the ER–mitochondria interface and inflammation was first recognized a few years ago with the observation that reactive oxygen species (ROS) promote the activation of NOD-like receptor protein 3 (NLRP3) inflammasomes13. The inflammasome is a multiprotein complex composed of a sensor protein, an adaptor protein called apoptosis-associated speck-like protein, containing a caspase-recruitment domain (ASC) and pro-caspase 1, a cysteine protease. There are four subfamilies of inflammasomes depending on the sensor molecule: NLRP3, NLRP1, NLRC4 (NLR family, CARD domain containing 4), and AIM2 (absent in melanoma 2)14. These sensor molecules can sense diverse stimulators ranging from microbial products (pathogen-associated molecular patterns, PAMPs) to host-derived damage signals (damage-associated molecular patterns, DAMPs) or any other insults that may occur within the cytosol. Once assembled, pro-caspase 1 is autoprocessed by proximity to active caspase 1, which induces the maturation of pro-interleukin-1β (IL-1β) or pro-IL-18 to their activated form. Among the inflammasomes, NLRP3 is the most studied and characterized due to its implication in the pathogenesis of different human diseases15. To date, the NLRP3 complex is the only inflammasome complex to be described as associated with MAMs13. Despite receiving much attention and investigation16,17, the activation of the NLRP3 inflammasome remains an enigmatic mechanism. So far, a two-step process has been proposed for the activation of NLRP3: (i) a priming step triggered by the interaction of Toll-like endosomal receptors (TLRs) with their ligands, leading to the transcription of NLRP3 and pro-IL-1β by nuclear factor kB (NF-κB), and (ii) an activation step promoted by several stimulators that initiates complex assembly in a manner dependent on K+ efflux through P2×7 activation18, lysosomal rupture, or mitochondrial ROS19. Moreover, different models have been proposed to explain the role of Ca2+-signaling in NLRP3 activation (for a detailed review, see ref. 20). Lee et al. proposed a critical role for calcium-sensing receptor (CASR) in activating the NLRP3 inflammasome that is mediated by increased intracellular Ca2+ and decreased cellular cyclic AMP (cAMP)21. An alternative model proposed that sustained Ca2+ influx (via ER Ca2+ release channels) triggers mitochondrial Ca2+ overload and associated mitochondrial destabilization22 and is characterized by high levels of ROS production and the induction of mitochondrial permeability transition pore (mPTP)23. Supporting this model, Misawa et al. observed that during inflammasome formation microtubules drive the perinuclear migration of mitochondria that results in subsequent apposition of ASC on mitochondria to NLRP3 on the ER24. NLRP3 is expressed in most tissues but predominantly in macrophages. In the inactive state, NLRP3 localizes to the ER membrane and cytosol, but when activated both NLRP3 and its adaptor ASC relocate to the MAM fraction (Fig. 1) where they detect increased ROS production from damaged mitochondria13. In particular, respiratory chain inhibitors (like complex I inhibitor rotenone) activate the inflammasome implicating a loss of the ΔΨm and ROS accumulation. Therefore, by virtue of its ER–mitochondria localization upon activation, the NLRP3 inflammasome is strategically located to sense signals emanating from mitochondria. [Figure: Mitochondria-associated ER membranes are important sites for NLRP3 inflammasome activationUnder non-stimulatory conditions, most NLRP3 protein localizes to cytoplasmic